Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors

References

• Ghosn M, Kattan J, El Karak F, et al. Renal cell carcinoma management: real-world practice and challenges at a national level. Future Oncol. 2023;19(12):863–872. doi: 10.2217/fon-2021-1189
   PubMed Web of Science ®Google Scholar
• Bahadoram S, Davoodi M, Hassanzadeh S, et al. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol. 2022;39(3).
   PubMedGoogle Scholar
• Garje R, An J, Greco A, et al. The future of immunotherapy-based combination therapy in metastatic renal cell carcinoma. Cancers (Basel). 2020;12(1):143. doi:10.3390/cancers12010143
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277–1290. doi: 10.1056/NEJMoa1712126.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer. 2020;8(2):e000891. doi: 10.1136/jitc-2020-000891
   PubMed Web of Science ®Google Scholar
• Ueda K, Suekane S, Kurose H, et al. Improved survival of real-world Japanese patients with advanced renal cell carcinoma treated with immuno-oncology combination therapy. Anticancer Res. 2022;42(9):4573–4580. doi: 10.21873/anticanres.15960
   PubMed Web of Science ®Google Scholar
• Bosma NA, Warkentin MT, Gan CL, et al. Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Open Sci. 2022;37:14–26. doi: 10.1016/j.euros.2021.12.007.
   PubMedGoogle Scholar
• Bai R, Lv Z, Xu D, et al. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res. 2020;8(34). doi: 10.1186/s40364-020-00209-0
   PubMed Web of Science ®Google Scholar
• Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4(3):250–255. doi:10.1007/s11912-002-0023-1
   PubMedGoogle Scholar
• Stenman M, Laurell A, Lindskog M. Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma. Med Oncol. 2014;31(3):841. doi:10.1007/s12032-014-0841-7
   PubMed Web of Science ®Google Scholar
• Ishihara H, Tachibana H, Takagi T, et al. Predictive impact of peripheral blood markers and C-Reactive protein in Nivolumab therapy for metastatic renal cell carcinoma. Target Oncol. 2019;14(4):453–463. doi: 10.1007/s11523-019-00660-6
   PubMed Web of Science ®Google Scholar
• Montero AJ, Diaz-Montero CM, Millikan RE, et al. Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-α: association of pretreatment serum levels with survival. Ann Oncol. 2009;20(10):1682–1687. doi: 10.1093/annonc/mdp054
   PubMed Web of Science ®Google Scholar
• Fukuda S, Saito K, Yasuda Y, et al. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. J Immunother Cancer. 2021;9(2):e001564. doi: 10.1136/jitc-2020-001564
   PubMed Web of Science ®Google Scholar
• Lalani AA, Xie W, Martini DJ, et al. Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018;6(1):5. doi: 10.1186/s40425-018-0315-0
   PubMed Web of Science ®Google Scholar
• Yanagisawa T, Mori K, Katayama S, et al. Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy. 2022;14(9):709–725. doi: 10.2217/imt-2021-0207
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202–206. doi: 10.1038/s41588-018-0312-8
   PubMed Web of Science ®Google Scholar
• Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–150. doi:10.1038/s41568-019-0116-x
   PubMed Web of Science ®Google Scholar
• Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278. doi:10.1186/s40425-019-0768-9
   PubMed Web of Science ®Google Scholar
• Valero C, Lee M, Hoen D, et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 2021;12(1):729. doi: 10.1038/s41467-021-20935-9
   PubMed Web of Science ®Google Scholar
• Ma Y, Ma X, Wang J, et al. Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis. World J Surg Oncol. 2022;20(1):242. doi:10.1186/s12957-022-02695-y
   PubMed Web of Science ®Google Scholar
• Han CL, Meng GX, Ding ZN, et al. The predictive potential of the baseline C-Reactive protein levels for the efficiency of immune checkpoint inhibitors in cancer patients: a systematic review and meta-analysis. Front Immunol. 2022;13:827788. doi: 10.3389/fimmu.2022.827788
   PubMedGoogle Scholar
• Yamamoto Y, Matsuyama H, Matsumoto H, et al. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma. Jpn J Clin Oncol. 2020;50(2):214–220. doi: 10.1093/jjco/hyz168
   PubMed Web of Science ®Google Scholar
• Sang YB, Yang H, Lee WS, et al. High serum levels of IL-6 predict poor responses in patients treated with pembrolizumab plus axitinib for advanced renal cell carcinoma. Cancers (Basel). 2022;14(23):5985. doi: 10.3390/cancers14235985
   PubMed Web of Science ®Google Scholar
• Spisarova M, Melichar B, Juranova J, et al. Biomarkers of inflammation and progression during immunotherapy in patients with metastatic renal cell carcinoma. In Vivo. 2023;37(1):393–399. doi: 10.21873/invivo.13091
   PubMed Web of Science ®Google Scholar
• Werner-Felmayer G, Werner ER, Fuchs D, et al. Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment. Cancer Res. 1990;50(10):2863–2867.
   PubMed Web of Science ®Google Scholar
• Pingle SK, Tumane RG, Jawade AA. Neopterin: Biomarker of cell-mediated immunity and potent usage as biomarker in silicosis and other occupational diseases. Indian J Occup Environ Med. 2008;12(3):107–111. doi:10.4103/0019-5278.44690
   PubMedGoogle Scholar
• Fuchs D, Weiss G, Wachter H. Neopterin, biochemistry and clinical use as a marker for cellular immune reactions. Int Arch Allergy Immunol. 1993;101(1):1–6. doi:10.1159/000236491
   PubMed Web of Science ®Google Scholar
• Fuchs D, Weiss G, Reibnegger G, et al. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci. 1992;29(3–4):307–344. doi:10.3109/10408369209114604
   PubMed Web of Science ®Google Scholar
• Melichar B, Solichová D, Freedman RS. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer. 2006;16(1):240–252. doi:10.1111/j.1525-1438.2006.00294.x
   PubMed Web of Science ®Google Scholar
• Lanser L, Kink P, Egger EM, et al. Inflammation-Induced Tryptophan Breakdown is Related with anemia, fatigue, and depression in cancer. Front Immunol. 2020;11:249. doi: 10.3389/fimmu.2020.00249
   PubMed Web of Science ®Google Scholar
• Krčmová LK, Matoušová K, Javorská L, et al. Neopterin and kynurenine in serum and urine as prognostic biomarkers in hospitalized patients with delta and omicron variant SARS-CoV-2 infection. Clin Chem Lab Med. 2023;61(11):2053–2064. doi: 10.1515/cclm-2023-0381
   PubMed Web of Science ®Google Scholar
• Thomas B, Bipath P, Viljoen M. Comparison between plasma neopterin and the urine neopterin: creatinine ratio as inflammatory biomarkers. Afr Health Sci. 2019;19(3):2407–2413. doi:10.4314/ahs.v19i3.14
   PubMed Web of Science ®Google Scholar
• Wachter H, Hausen A, Grassmayr K. Increased urinary excretion of neopterin in patients with malignant tumors and with virus diseases. Hoppe Seylers Z Physiol Chem. 1979;360(12):1957–1960.
   PubMedGoogle Scholar
• Melichar B, Spisarova M, Bartouskova M, et al. Neopterin as a biomarker of immune response in cancer patients. Ann Transl Med. 2017;5(13):280. doi:10.21037/atm.2017.06.29
   PubMed Web of Science ®Google Scholar
• Frick J, Aulitzky W, Fuchs D, et al. The value of urinary neopterin as an immunological parameter in patients with malignant tumors of the genitourinary tract. Urol Int. 1985;40(3):155–159. doi: 10.1159/000281071
   PubMed Web of Science ®Google Scholar
• Aulitzky W, Frick J, Fuchs D, et al. Significance of urinary neopterin in patients with malignant tumors of the genitourinary tract. Cancer. 1985;55(5):1052–1055. doi:10.1002/1097-0142(19850301)55:5<1052:AID-CNCR2820550521>3.0.CO;2-9
   PubMed Web of Science ®Google Scholar
• Yoshida N, Ikemoto S, Narita K, et al. Serum neopterin levels in renal cell carcinoma. Pteridines. 2000;11(4):133–136. doi: 10.1515/pteridines.2000.11.4.133
   Web of Science ®Google Scholar
• Azuma K, Xiang H, Tagami T, et al. Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model. J Immunother Cancer. 2022;10(5):e004420. doi: 10.1136/jitc-2021-004420
   PubMed Web of Science ®Google Scholar
• Asano T, Nakajima F, Odajima K, et al. Urinary neopterin levels in patients with genitourinary tract malignancies. Nihon Hinyokika Gakkai Zasshi. 1997;88(1):53–58. doi:10.5980/jpnjurol1989.88.53
   PubMedGoogle Scholar
• Musaelyan AA, Lapin SV, Urtenova MA, et al. Inflammatory and autoimmune predictive markers of response to anti‑PD‑1/PD‑L1 therapy in NSCLC and melanoma. Exp Ther Med. 2022;24(3):557. doi: 10.3892/etm.2022.11495
   PubMed Web of Science ®Google Scholar
• Denz H, Fuchs D, Huber H, et al. Correlation between neopterin, interferon-gamma and haemoglobin in patients with haematological disorders. Eur J Haematol. 1990;44(3):186–189. doi: 10.1111/j.1600-0609.1990.tb00374.x
   PubMed Web of Science ®Google Scholar
• Yip SM, Wells C, Moreira R, et al. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Cancer. 2018;124(18):3677–3683. doi: 10.1002/cncr.31595
   PubMed Web of Science ®Google Scholar
• Stukalin I, Wells JC, Graham J, et al. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Curr Oncol. 2019;26(2):175–179. doi: 10.3747/co.26.4595
   PubMed Web of Science ®Google Scholar
• Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236(1):219–242. doi: 10.1111/j.1600-065X.2010.00923.x
   PubMed Web of Science ®Google Scholar
• Gianchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev. 2013;12(11):1091–1100. doi:10.1016/j.autrev.2013.05.003
   PubMed Web of Science ®Google Scholar
• Chen J, Jiang CC, Jin L, et al. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27(3):409–416. doi:10.1093/annonc/mdv615
   PubMed Web of Science ®Google Scholar
• Dudani S, Savard MF, Heng DYC. An update on predictive biomarkers in metastatic renal cell carcinoma. Eur Urol Focus. 2020;6(1):34–36. doi:10.1016/j.euf.2019.04.004
   PubMedGoogle Scholar
• Motzer RJ, McDermott DF, Escudier B, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer. 2022;128(11):2085–2097. doi: 10.1002/cncr.34180
   PubMed Web of Science ®Google Scholar
• Albiges L, Tannir NM, Burotto M, et al. First-line Nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 trial. Eur Urol. 2022;81(3):266–271. doi: 10.1016/j.eururo.2021.10.001
   PubMed Web of Science ®Google Scholar
• Mori K, Abufaraj M, Mostafaei H, et al. The predictive value of programmed death Ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors: a systematic review and meta-analysis. Eur Urol. 2021;79(6):783–792. doi: 10.1016/j.eururo.2020.10.006
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. doi: 10.1056/NEJMoa1816714
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Robbins PB, Powles T, et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN renal 101 trial. Nat Med. 2020;26(11):1733–1741. doi: 10.1038/s41591-020-1044-8
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–841. doi: 10.1056/NEJMoa2026982
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021;384(14):1289–1300. doi: 10.1056/NEJMoa2035716.
   PubMed Web of Science ®Google Scholar
• Turajlic S, Litchfield K, Xu H, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017;18(8):1009–1021. doi: 10.1016/S1470-2045(17)30516-8
   PubMed Web of Science ®Google Scholar
• Kim J, Park JY, Shin SJ, et al. Neo-Fs Index: a novel immunohistochemical biomarker panel predicts survival and response to anti-angiogenetic agents in clear cell renal cell carcinoma. Cancers (Basel). 2021;13(6):1199. doi:10.3390/cancers13061199
   PubMed Web of Science ®Google Scholar
• Strickler JH, Hanks BA, Khasraw M. Tumor mutational burden as a predictor of immunotherapy response: is more always better? Clin Cancer Res. 2021;27(5):1236–1241. doi:10.1158/1078-0432.CCR-20-3054
   PubMed Web of Science ®Google Scholar
• Braun DA, Hou Y, Bakouny Z, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26(6):909–918. doi: 10.1038/s41591-020-0839-y
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Choueiri TK, McDermott DF, et al. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J Immunother Cancer. 2022;10(3):e004316. doi: 10.1136/jitc-2021-004316
   PubMed Web of Science ®Google Scholar
• Wang M, Zhao J, Zhang L, et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8(5):761–773. doi: 10.7150/jca.17648
   PubMed Web of Science ®Google Scholar
• Kawashima A, Uemura M, Nonomura N. Importance of multiparametric evaluation of immune-related T-Cell markers in Renal-Cell Carcinoma. Clin Genitourin Cancer. 2019;17(6):e1147–e1152. doi:10.1016/j.clgc.2019.07.021
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang E, Long J, et al. Immune infiltration in renal cell carcinoma. Cancer Sci. 2019;110(5):1564–1572. doi: 10.1111/cas.13996
   PubMed Web of Science ®Google Scholar
• Ascierto ML, McMiller TL, Berger AE, et al. The intratumoral balance between metabolic and immunologic gene expression is associated with anti–PD-1 response in patients with Renal Cell Carcinoma. Cancer Immunol Res. 2016;4(9):726–733. doi: 10.1158/2326-6066.CIR-16-0072
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Banchereau R, Hamidi H, et al. MoleculaR subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell. 2020;38(6):803–817.e4. doi: 10.1016/j.ccell.2020.10.011
   PubMed Web of Science ®Google Scholar
• Au L, Hatipoglu E, Robert de Massy M, et al. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell. 2021;39(11):1497–1518.e11. doi: 10.1016/j.ccell.2021.10.001
   PubMed Web of Science ®Google Scholar
• McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749–757. doi: 10.1038/s41591-018-0053-3
   PubMed Web of Science ®Google Scholar
• Teng MW, Ngiow SF, Ribas A, et al. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75(11):2139–2145. doi:10.1158/0008-5472.CAN-15-0255
   PubMed Web of Science ®Google Scholar
• Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22(8):1865–1874. doi:10.1158/1078-0432.CCR-15-1507
   PubMed Web of Science ®Google Scholar
• Albiges L, Flippot R, Escudier B. Immune checkpoint inhibitors in metastatic clear-cell renal cell carcinoma: is PD-L1 expression useful? Eur Urol. 2021;79(6):793–795. doi:10.1016/j.eururo.2021.02.040
   PubMed Web of Science ®Google Scholar
• First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma. 2024. doi: 10.3030/101104801
   Google Scholar
• Callea M, Albiges L, Gupta M, et al. Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol Res. 2015;3(10):1158–1164. doi: 10.1158/2326-6066.CIR-15-0043
   PubMed Web of Science ®Google Scholar